Scope, Claims, and US Patent Landscape for Drug Patent 12,102,609 (Solriamfetol Breastfeeding Mitigation Methods)
What do the asserted claims cover?
US Drug Patent 12,102,609 claims method claims focused on decreasing infant adverse-event potential from solriamfetol exposure via breast milk by timing breastfeeding after a once-daily 150 mg oral solriamfetol dose and imposing upper limits on cumulative solriamfetol excretion into milk.
Across the independent frameworks, the scope turns on three claim-dominant constraints:
- Dose and regimen
- “administering solriamfetol orally at a once-daily dose of about 150 mg”
- Feeding delay
- “feeding the infant breast milk … at least about 5 hours after administering”
- Quantitative excretion limit
- Claim family (8-hour window): “cumulative amount … excreted in breast milk over 8 hours … about 0.26 mg or lower”
- Claim family (24-hour window): “cumulative amount … excreted … over 24 hours … about 0.35 mg or lower”
- One independent method uses “cumulative median amount” (8-hour).
The claims also include dependent narrowing around:
- specific infant adverse events (agitation, insomnia, reduced weight gain),
- postpartum timing windows (1 day to 24 months; with sub-range 10 days to 52 weeks),
- treated conditions (narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, ADHD, cognitive impairment, binge eating disorder),
- maternal age (18 to 45 years),
- and an infant outcome statement (“infant does not experience” defined adverse events).
How are the claim families structured?
The text provided includes three distinct method groupings that differ by the quantitative criterion window and metric:
Claim Set A (independent method with 8-hour cap)
- Claim 1: once-daily ~150 mg; feed ≥ about 5 hours after dosing; cumulative amount over 8 hours ≤ about 0.26 mg
- Claim 2-6: adverse-event type; covered maternal disorders; infant outcome; postpartum windows
Claim Set B (independent method with 24-hour cap)
- Claim 7: once-daily ~150 mg; feed ≥ about 5 hours after dosing; cumulative amount over 24 hours ≤ about 0.35 mg
- Claim 8-12: same style dependent features with 24-hour quantification
Claim Set C (independent method using median metric over 8 hours)
-
Claim 13: same dosing/regimen and delay; cumulative median amount over 8 hours ≤ about 0.26 mg
-
Claim 14-18: dependent features
-
Claim 20 mirrors Claim 13 but uses 24-hour median/amount metric:
- Claim 20: feed ≥ about 5 hours; cumulative median amount over 24 hours ≤ about 0.35 mg
This matters for freedom-to-operate because switching between “amount” and “median amount” can alter whether a competing protocol is within literal scope, depending on how a practitioner measures exposure and what study design is used to support compliance.
What are the independent claim elements (verbatim scope logic)?
Independent method (8-hour cumulative amount ≤ 0.26 mg)
Claim 1 requires all of the following, in combination:
- administering solriamfetol orally, once-daily, about 150 mg
- feeding breast milk obtained from a human subject treated with solriamfetol
- feeding occurs at least about 5 hours after administering
- cumulative amount of solriamfetol excreted in breast milk over 8 hours is about 0.26 mg or lower
- purpose context: “decreasing the potential for adverse events from solriamfetol in an infant fed breast milk”
Independent method (24-hour cumulative amount ≤ 0.35 mg)
Claim 7 repeats the same structure but replaces the quantitative window:
- cumulative amount over 24 hours ≤ about 0.35 mg
- feeding still constrained by ≥ about 5 hours
Independent method (median metric)
Claims 13 and 20 replicate the same regimen and timing and substitute:
- “cumulative median amount … over 8 hours about 0.26 mg or lower” (Claim 13)
- “cumulative median amount … over 24 hours about 0.35 mg or lower” (Claim 20)
How do the dependent claims narrow the scope?
Infant adverse event enumeration
The claims tie “potential adverse events” to a defined set:
- Agitation
- Insomnia
- Reduced weight gain
Examples:
- Claim 2 and Claim 8 and Claim 16 and Claim 23 define the adverse events as one or more of those three.
- Claims 4, 10, 15, 22 add an infant outcome limitation: “infant does not experience” those adverse events due to solriamfetol exposure.
Operationally, these dependent clauses sharpen evidentiary expectations for clinical protocols, labeling, and study endpoints, but they also increase literal infringement specificity: an alleged infringer would need not only timing and excretion cap compliance but also to practice within the “does not experience” boundary if asserting strict literal alignment with those dependent claims.
Maternal disease/indication coverage
Dependent claim sets specify that solriamfetol is administered for:
- narcolepsy
- excessive daytime sleepiness
- obstructive sleep apnea
- attention deficit/hyperactivity disorder (ADHD)
- cognitive impairment
- binge eating disorder
This set appears in:
From a landscape standpoint, it reduces ambiguity by anchoring to the solriamfetol indication universe the patent owner is targeting for breastfeeding mitigation.
Postpartum timing constraints
Two tiers:
- Claim 5/11/17/24: human subject is from 1 day to 24 months postpartum
- Claim 6/12/18/25: sub-range 10 days to 52 weeks postpartum
This is a key design constraint. A protocol that includes breastfeeding for a postpartum timing outside those ranges could avoid certain dependent claim coverage, but not necessarily the independent claims, which do not include postpartum limits.
Maternal age constraint
- Claims 19 and 26: subject age between 18 and 45 years
Only two dependent claims incorporate this limitation; thus, age is not required for the core independent methods.
Claim language that will matter in enforcement and validity challenges
1) “about” creates flexibility but still drives measurable criteria
All quantitative cutoffs use “about”:
- 8-hour cap: “about 0.26 mg or lower”
- 24-hour cap: “about 0.35 mg or lower”
- all with “at least about 5 hours”
This will widen the zone in infringement analyses, but it still forces measurement. Any noncompliant protocol that exceeds these caps could reduce infringement risk even if the delay is satisfied.
2) “cumulative amount” vs “cumulative median amount”
Claims 13 and 20 use “median amount,” which implies a population-distribution metric. Competitors that design studies around mean exposure or individual conservative exposure rather than median may still practice timing, but the literal measurement standard can differ.
3) “feeding the infant breast milk … obtained from a human subject treated with solriamfetol”
This ties the milk source to a treated subject, limiting indirect arguments that rely on generic milk substitution or third-party processing without the claimed source link.
4) “decreasing the potential for adverse events”
This is a method purpose statement layered over concrete steps. It may be used to frame interpretation of what constitutes the “method” in a case, but the claim also has objective constraints (timing and exposure caps).
US patent landscape implications: where this claim set likely positions itself
Without the full bibliographic record (filing, priority, assignee, and family members), the most defensible landscape analysis is based on what the claims operationalize. The patent is built to capture a narrow, clinically actionable protocol:
- Specific dose: ~150 mg once daily
- Specific post-dose breastfeeding delay: ≥ about 5 hours
- Specific exposure thresholds: 8-hour (≤ 0.26 mg) and 24-hour (≤ 0.35 mg)
- Specific measurement basis: cumulative amount and cumulative median amount
Likely “design-around” levers
Any competitor, clinician, or payer protocol seeking to reduce infringement exposure will focus on at least one lever:
- Change the breastfeeding delay (either less than the claimed “at least about 5 hours” or exceed it).
- Note: exceeding delay can still fall within the claim if exposure remains under caps.
- Change dose timing or dosing amount
- The claim is anchored on once-daily about 150 mg. Different dose (lower, higher, divided dosing) can potentially avoid literal claim elements.
- Demonstrate that cumulative exposure is above the thresholds
- If the measured cumulative amount or median exceeds the claimed caps, the method may fall outside literal scope.
- Use protocols targeting different measurable endpoints
- For example, exposure expressed differently (absolute maternal plasma levels or AUC) is not a direct substitute for the claims’ milk excretion metrics.
- Restrict to populations not covered by dependent claims
- Postpartum and maternal age dependent claims may be avoided by restricting protocol to outside those windows, while independent claim risk remains.
Likely “claim strength” relative to enforcement
- The method is not broad across all solriamfetol breastfeeding use. It is tethered to a dose and a measurement-based exposure cap.
- That narrowness improves clarity and reduces prior art overlap in many enforcement settings but can increase obviousness vulnerability if the underlying pharmacokinetic relationships and timing-and-dosing measurements were already known in the field.
- The enforcement question becomes technical: whether a given protocol results in cumulative excretion or median excretion at or below the claimed thresholds.
Practical scope summary for business decisions
A protocol will likely fall within the core claim scope if it matches the following “three-condition block”:
- Solriamfetol: oral once daily ~150 mg
- Breastfeeding timing: feed milk ≥ ~5 hours after dosing
- Milk solriamfetol exposure: cumulative (8-hour) ≤ ~0.26 mg or cumulative (24-hour) ≤ ~0.35 mg (or median variants for claims 13/20)
Dependent constraints add additional eligibility features (infant adverse event avoidance, postpartum ranges, maternal age, and indication).
Key Takeaways
- US Drug Patent 12,102,609 is an enforcement-ready set of method claims that combine dosing, breastfeeding timing, and quantified milk excretion thresholds for solriamfetol.
- The independent claims are anchored on once-daily ~150 mg, breastfeeding ≥ about 5 hours after dosing, and caps on cumulative milk solriamfetol excretion:
- ≤ about 0.26 mg over 8 hours
- ≤ about 0.35 mg over 24 hours
- Claims 13 and 20 introduce a median-based exposure metric, which can be pivotal in both infringement mapping and evidence design.
- Dependent claims narrow to specific adverse events (agitation, insomnia, reduced weight gain), postpartum windows, maternal age, and treated indications, but the core independent scope does not require those dependent limitations.
FAQs
1) Does the patent claim cover any breastfeeding while taking solriamfetol?
No. It claims a specific method: oral once-daily about 150 mg and breastfeeding at least about 5 hours after dosing, plus exposure limits in milk.
2) Are the exposure thresholds the same in every independent claim?
No. There are two main thresholds (0.26 mg for 8 hours; 0.35 mg for 24 hours) and two metric types (cumulative “amount” vs “median amount”).
3) Can a protocol that feeds earlier than 5 hours still fall within the claims?
No. The feeding step requires “at least about 5 hours” after administering in the independent claims.
4) Do dependent claims require proof that the infant does not experience side effects?
Some dependent claims add an explicit outcome limitation (infant does not experience agitation, insomnia, or reduced weight gain due to solriamfetol exposure).
5) Does the patent require solriamfetol to be prescribed for a particular disorder?
The independent claims focus on the method steps and exposure metrics. Dependent claims include disorder lists (narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, ADHD, cognitive impairment, binge eating disorder).
References
[1] User-provided claim text for US Drug Patent 12,102,609.
